Lupin Share Price Today | Stock Price & Lupin Share Screener
As of October 21, 2026, the live Lupin share price (NSE: LUPIN) is ₹1,964.00 on NSE and ₹1,957.00 on BSE, up 1.28% from the previous close, with shares trading between ₹1,929.00 and ₹1,964.00 in today's trading session, and a 52-week range of ₹1,918.70–₹2,514.80. Check LUPIN 52-week high low for the annual price range and momentum. Use the Lupin stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Lupin opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹8,348 and net income of ₹1,417, with EBITDA of ₹2,520, an operating margin of 29.0% and a profit margin of 17.0%.
Lupin Share Price Chart
Track the current stock price of Lupin with an interactive chart. Analyse LUPIN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Lupin stock quote in one place.
The quote of ₹1,964.00 sits between the 52-week low of ₹1,918.70 and the 52-week high of ₹2,514.80, and the latest session moved 1.28% from the previous close.
Lupin Company Profile - Fundamental Screener
Screen Lupin company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LUPIN shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with M D Gupta listed as chairperson or CEO, and it trades under ISIN INE326A01037.
Business Overview
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Company Details
Classification
Identifiers and Leadership
Lupin Balance Sheet Screener
Screen LUPIN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹38,365, up from ₹29,205 in 2025.
Latest statistics put total assets at ₹38,365 and shareholder funds at ₹22,513, with a leverage ratio of 0.30.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 38,365 | 29,205 | 23,997 | 22,956 | 21,821 | 23,610 | 24,984 | 27,949 | 26,305 | 26,607 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 10,994 | 9,719 | 8,878 | 8,355 | 7,382 | 7,881 | 7,938 | 11,087 | 10,362 | 11,033 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3,200 | 2,949 | 1,122 | 1,148 | 1,101 | 1,316 | 3,178 | 8,030 | 7,593 | 6,955 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 22,513 | 17,294 | 14,374 | 12,543 | 12,222 | 13,858 | 12,581 | 13,789 | 13,617 | 13,532 |
| Share Capital | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 90 | 90 |
| Reserves & Surplus | 22,357 | 17,112 | 14,199 | 12,374 | 12,062 | 13,712 | 12,446 | 13,652 | 13,487 | 13,407 |
Lupin Income Statement Screener - Profit & Revenue Analysis
Screen Lupin income statement and profit fundamentals. Analyze LUPIN quarterly results. Lupin reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹8,348 and net profit was ₹1,417, equal to earnings per unit of ₹30.95, at an operating margin of 29%.
In that period expenses were ₹5,827, interest cost ₹110 and tax ₹600. The next period listed, 2026-Mar, shows revenue of ₹7,533 and net profit of ₹1,469.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 8,348 | 7,533 | 7,215 | 6,921 | 6,243 | 5,619 | 4,924 | 5,582 | 5,539 | 5,672 | 4,368 | 4,765 | 4,980 | 5,109 | 3,880 |
| Expenses | 5,827 | 5,120 | 5,332 | 4,706 | 4,541 | 4,346 | 3,964 | 4,359 | 4,332 | 4,412 | 3,852 | 3,958 | 4,121 | 4,160 | 3,615 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 2,520 | 2,412 | 1,883 | 2,215 | 1,702 | 1,273 | 960 | 1,223 | 1,207 | 1,261 | 515 | 807 | 859 | 950 | 265 |
| Operating Profit % | 29.00% | 31.00% | 25.00% | 31.00% | 26.00% | 22.00% | 19.00% | 21.00% | 21.00% | 21.00% | 11.00% | 17.00% | 17.00% | 18.00% | 6.00% |
| Depreciation | 453 | 447 | 313 | 317 | 299 | 393 | 457 | 248 | 257 | 272 | 264 | 235 | 248 | 257 | 327 |
| Interest | 110 | 120 | 115 | 108 | 92 | 89 | 71 | 68 | 71 | 67 | 93 | 86 | 81 | 74 | 42 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 2,017 | 1,928 | 1,522 | 2,007 | 1,416 | 896 | 498 | 993 | 1,055 | 1,071 | 259 | 559 | 630 | 736 | -85 |
| Tax | 600 | 459 | 342 | 522 | 194 | 114 | 130 | 188 | 195 | 212 | 16 | 106 | 134 | 117 | 427 |
| Net Profit | 1,417 | 1,469 | 1,181 | 1,485 | 1,222 | 782 | 368 | 806 | 860 | 859 | 242 | 453 | 495 | 619 | -512 |
| EPS | 30.95 | 34.83 | 25.74 | 32.36 | 26.70 | 16.93 | 7.89 | 17.58 | 18.70 | 18.75 | 5.19 | 9.94 | 10.76 | 13.47 | -11.40 |
Lupin Cash Flow Screener - Liquidity Fundamentals
Screen LUPIN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹7,335, and net cash flow was an inflow of ₹2,624.
Over the same period, investing activities used ₹3,865 and financing activities used ₹846.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 7,335 | 3,000 | 3,648 | 1,897 | 367 | 1,822 | 1,469 | 1,666 | 1,751 | 4,114 |
| Investing Activities | -3,865 | -4,172 | -1,712 | -1,287 | 1,292 | -1,240 | 1,107 | -3,283 | 470 | -2,527 |
Financing and Net Cash | ||||||||||
| Financing Activities | -846 | 1,732 | -2,184 | -337 | -1,572 | -1,885 | -891 | 744 | -1,492 | 433 |
| Net Cash Flow | 2,624 | 560 | -248 | 273 | 87 | -1,303 | 1,685 | -872 | 729 | 2,019 |
Lupin Shareholding Pattern Screener
See Lupin shareholding pattern with promoter, FII, and DII holdings. Check Lupin promoter holding and ownership changes for LUPIN on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 46.84%, foreign institutions 23.28%, domestic institutions 23.78% and the public 5.13%, spread across 297,301 shareholders.
The shareholder count was 297,301 in 2026-Sept, compared with 290,411 in 2026-Mar.
| Item | 2026-Sept | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 46.84% | 46.86% | 46.85% | 46.92% | 46.90% | 46.90% | 46.89% | 47.01% |
Institutional Investors | ||||||||
| FII Holding | 23.28% | 21.71% | 22.42% | 21.46% | 21.25% | 20.49% | 21.49% | 18.28% |
| DII Holding | 23.78% | 25.32% | 24.65% | 25.41% | 25.56% | 26.55% | 25.58% | 27.76% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 5.13% | 5.05% | 5.06% | 5.10% | 5.23% | 5.12% | 5.10% | 5.70% |
| Other Holding | 0.97% | 1.06% | 1.02% | 1.10% | 1.05% | 0.94% | 0.93% | 1.23% |
| Shareholder Count | 297,301 | 290,411 | 300,283 | 283,210 | 286,604 | 280,256 | 288,931 | 280,248 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Lupin. Lupin dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹18.00 per unit for 2026-March, a yield of 0.93%, compared with ₹12.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹18.00, ₹12.00 and ₹8.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹18.00 | 0.93% |
| 2025-March | ₹12.00 | 0.52% |
| 2024-March | ₹8.00 | 0.39% |
| 2023-March | ₹4.00 | 0.25% |
| 2022-March | ₹4.00 | 0.61% |
| 2021-March | ₹6.50 | 0.87% |
| 2020-March | ₹6.00 | 0.59% |
| 2019-March | ₹5.00 | 0.85% |
| 2018-March | ₹5.00 | 0.68% |
| 2017-March | ₹7.50 | 1.02% |
Lupin Stock Index Membership - Nifty & Sensex
See which indices include Lupin stock. Check LUPIN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 43 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE100.
Complete Index List
Lupin Market Events Screener - Corporate Actions
Get Lupin corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Lupin stock events that may affect LUPIN share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 6, 2026, with a record date of August 6, 2026.
It is followed by Annual General Meeting dated August 4, 2026 and Dividend dated July 17, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-06 | 2026-08-06 | Quarterly Result Announcement | NA | -5.12% |
| 2026-08-04 | 2026-08-04 | Annual General Meeting | NA | -4.59% |
| 2026-07-17 | 2026-07-17 | Dividend | ₹ 18.00 /share | 2.34% |
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | 5.68% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 2.72% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 2.76% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | 1.23% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -2.52% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 12.00 /share | -5.80% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -2.12% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 1.65% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 0.66% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 9.82% |
| 2024-07-16 | 2024-07-16 | Dividend | ₹ 8.00 /share | 10.68% |
| 2023-07-14 | 2023-07-14 | Dividend | ₹ 4.00 /share | 27.11% |
Lupin Competitors Screener - Peer Stocks Comparison
Screen LUPIN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 418,708 | 34.55 | 61,674 | 12.69% | 11,565 | 35.10 |
| Divis Laboratories | 243,966 | 82.50 | 11,067 | 13.95% | 2,568 | 48.83 |
| Torrent Pharmaceuticals | 173,212 | 80.28 | 13,886 | 20.34% | 2,138 | 32.47 |
| Zydus Life Science | 111,451 | 24.17 | 27,658 | 17.64% | 5,026 | 43.74 |
| Laurus Labs | 108,738 | 102.20 | 6,868 | 22.01% | 890 | 52.29 |
| Cipla | 106,153 | 32.04 | 29,045 | 2.24% | 3,870 | 37.29 |
| Dr Reddys Laboratories | 103,876 | 32.56 | 35,059 | 3.90% | 4,158 | 60.36 |
| Mankind Pharma | 94,401 | 44.98 | 14,636 | 14.85% | 1,938 | 40.13 |
| Aurobindo Pharma | 90,841 | 25.04 | 34,145 | 5.56% | 3,503 | 34.96 |
| Lupin | 89,812 | 16.09 | 29,039 | 26.75% | 5,356 | 38.28 |
Lupin Company Announcements - News & Reports Screener
Screen LUPIN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 20, 2026.
The next most recent announcements are dated October 20, 2026 and October 20, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-20 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-10-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-20 | Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-16 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- ESG Rating | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-08 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-01 | Completion Of Buyback Of Shares By Multicare Pharmaceuticals Philippines Inc. | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-21 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-09-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-28 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- ESG Rating | - |
| 2026-08-25 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-08-24 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating | - |
| 2026-08-20 | Exclusive License Agreement With Visus Therapeutics Inc. U.S.A. | - |
| 2026-08-18 | Announcement under Regulation 30 (LODR)-Demise | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,964.00, within a 52-week range of ₹1,918.70 to ₹2,514.80. The P/E ratio is 16.09 and the P/B ratio is 3.98, with earnings per unit of ₹116.75. Market capitalisation stands at ₹89,811.75 Cr and the dividend yield is 0.92%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 22, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.